Zhang J, Wang Y, Luo W, Shi B, Zhu B, Si L
Department of Immunopathology, Xi'an Jiaotong University, Xi'an 710061, China.
Zhonghua Bing Li Xue Za Zhi. 2001 Aug;30(4):268-72.
To explore the patterns of TCR V beta gene families and the preferentially used V beta genes in intrathyroidal T lymphocytes (ITL) of patients with Graves disease and Hashimoto thyroiditis.
Thyroid tissues of 12 patients with Graves disease, and 15 patients with Hashimotos thyroiditis were used for RNA extraction. Then, the RNA was used as templates for RT-PCR with a panel of primers including 24 oligonucleotides specific for TCR V beta gene families as upstream primers and one oligonucleotide specific for C beta as downstream primer. The amplified products were subjected to electrophoresis in agarose gels and observed under UV light. The positive expression of TCR V beta gene was identified by comparing the products with the size of the designed V beta genes. The matched peripheral blood samples of 5 Graves patients, 5 Hashimoto thyroiditis patients and 7 normal subjects were also obtained and used as controls.
In 24 TCR V beta gene families tested for each individual sample, their average expressions were 5.3 +/- 1.2 and 13.4 +/- 3.0 in thyroid specimens of patients with Graves disease and Hashimoto thyroiditis, respectively, while those in the matched peripheral blood lymphocytes of the above two groups and normal controls were 23.0 +/- 1.0, 22.2 +/- 1.3 and 22.4 +/- 1.7, respectively. In addition, some of the TCR V beta genes such as V beta 3, V beta 5 and V beta 8 were more frequently used by intrathyroidal lymphocytes of Graves disease.
These data indicate the oligoclonality of the intrathyroidal T cell populations in patients with Graves disease. Also, those of the preferentially used TCR V beta genes can be regarded as molecular targets for specific immune intervention. In contrast, the loss of restriction of TCR V beta gene utilization exists in Hashimoto thyroiditis, which may be related to the recruitment of T lymphocytes in thyroid glands through this mechanism.
探讨格雷夫斯病和桥本甲状腺炎患者甲状腺内T淋巴细胞(ITL)中TCR Vβ基因家族模式及优先使用的Vβ基因。
取12例格雷夫斯病患者和15例桥本甲状腺炎患者的甲状腺组织提取RNA。然后,以RNA为模板,用一组引物进行逆转录聚合酶链反应(RT-PCR),其中包括24条针对TCR Vβ基因家族的寡核苷酸作为上游引物,1条针对Cβ的寡核苷酸作为下游引物。扩增产物在琼脂糖凝胶中进行电泳,并在紫外线下观察。通过将产物与设计的Vβ基因大小进行比较来鉴定TCR Vβ基因的阳性表达。还获取了5例格雷夫斯病患者、5例桥本甲状腺炎患者和7例正常受试者的匹配外周血样本作为对照。
在对每个个体样本检测的24个TCR Vβ基因家族中,格雷夫斯病患者和桥本甲状腺炎患者甲状腺标本中的平均表达分别为5.3±1.2和13.4±3.0,而上述两组匹配外周血淋巴细胞及正常对照中的平均表达分别为23.0±1.0、22.2±1.3和22.4±1.7。此外,格雷夫斯病甲状腺内淋巴细胞更频繁地使用一些TCR Vβ基因,如Vβ3、Vβ5和Vβ8。
这些数据表明格雷夫斯病患者甲状腺内T细胞群体具有寡克隆性。同样,优先使用的TCR Vβ基因可被视为特异性免疫干预的分子靶点。相比之下,桥本甲状腺炎存在TCR Vβ基因利用限制的丧失,这可能与通过该机制招募甲状腺内的T淋巴细胞有关。